Interesting article on Bloomberg this morning regarding Alzehimer’s disease. The article notes that J&J’s bapineuzumab for plaque eradication may be stumbling, notably there are some very severe side effects (including brain swelling), with no reported associated cognition benefits (even if plaque levels are retarded). Of course, this was anecdotal, but it does not bode well for a struggling class of therapy and the millions who are impacted by the disease.
Next week’s Alzheimer’s meeting will be interesting (sadly, I won’t attend this year). Coincidentally, I’m also very interested in a couple of upcoming studies to be published in the August issue of Journal of Alzheimer’s Disease. Are we close to a new enhanced understanding of Alzheimer’s?
1 comment:
Until the ultimate results of the bapinezumab trial are published we indeed have no choice but to deal with anecdotal case studies. Interestingly, the same day the Blommberg's article appeared another comment on the issue was published on one of the Associated Press websites (http://hosted.ap.org/dynamic/stories/U/US_MED_ALZHEIMERS_DRUGS?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT). This one describes a positive case study of patient receiving Baxter's Gammagard. I also regret missing ICAD this year...
Post a Comment